Clopidogrel vs Aspirin in Congestive Heart Failure (CACHE)

Phase 3

Withdrawn

• Conditions: Heart failure; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12609000440224
• Lead Sponsor: niversity of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-06-11
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Withdrawn
• Sex: All
• Target Recruitment: 1250

Inclusion Criteria

1. Men or women age >18 years
2. Symptomatic heart failure
3. Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) of >600pg/mL
OR NT-proBNP >400pg/mLa + Heart Failure (HF) hospitalisation within last 12 months
4. Treatment with an angiotensin converting enzyme (ACE) inhibitor (unless not tolerated) and ongoing treatment with a diuretic
5. Provision of written informed consent

Exclusion Criteria

1. Contraindication to aspirin or clopidogrel
2. Indication for chronic anti-coagulation
3. Heart failure due to a reversible cause or hypertrophic or infiltrative cardiomyopathy
4. Unstable heart failure or treatment regimen
5. Life-limiting systemic illness
6. Severe chronic obstructive pulmonary disease (COPD) (as evidenced by history of mechanical ventilation, need for home oxygen, or treatment with oral corticosteroids) for more than 3 continuous days within 12 months
7. Conditions that might interfere with protocol compliance

Study & Design

• Study Type: Interventional
• Study Design: Not specified